

# NOTIFICATION OF ATTENDANCE AND FORM FOR ADVANCE VOTING

The form must be received by Xspray Pharma AB (publ) no later than Wednesday 6 May 2026.

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Xspray Pharma AB (publ), Reg. No. 556649-3671 at the annual general meeting on Tuesday 12 May 2026. The voting right is exercised in accordance with the below marked voting options.

Name of the shareholder	Personal identity number/registration number

**Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity):** I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions

**Assurance (if the undersigned represents the shareholder by proxy):** I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked

<b>Place and date</b>	
<b>Signature</b>	
<b>Clarification of signature</b>	
<b>Telephone number</b>	<b>E-mail</b>

## Instructions to vote in advance:

- Complete all the information above.
- Select the preferred voting options below.
- Print, sign and send the form in the original to Xspray Pharma, "General meeting", Scheeles väg 2, SE-171 65 Solna, Sweden. A completed and signed form may also be submitted electronically and shall, in that case, be sent to [generalmeeting@xspray.com](mailto:generalmeeting@xspray.com).
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign.

- If the shareholder votes by proxy, a proxy shall be enclosed with the form. If the shareholder is a legal entity, a certificate of incorporation or an equivalent certificate of authority should be enclosed with the form.
- A shareholder whose shares have been registered in the name of a bank or securities institute must re-register its shares in its own name to vote. Instructions for this are included in the notice convening the meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (*i.e.* the advance voting in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented.

The form, together with any enclosed authorization documentation, shall be provided to Xspray no later than Wednesday 6 May 2026. An advance vote can be withdrawn up to and including Wednesday 6 May 2026 by contacting [generalmeeting@xspray.com](mailto:generalmeeting@xspray.com). Thereafter, the advance vote can only be withdrawn if the shareholder is present, in person or by proxy, at the general meeting.

One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. If a shareholder has voted in advance and attends the general meeting in person or through a proxy, the advance vote is still valid except to the extent the shareholder participates in a voting procedure at the general meeting or otherwise withdraws its casted advance vote. If the shareholder chooses to participate in a voting at the general meeting, the vote cast will replace the advance vote with regard to the relevant item on the agenda.

Note that the advance vote does not constitute a notification to participate in the general meeting at the venue in person or through proxy. Instructions for shareholders who wish to participate in the annual general meeting at the venue in person or represented by a proxy are included in the notice convening the meeting.

For complete proposals for the items on the agenda, kindly refer to the notice convening the meeting and the proposals on Xspray Pharma's webpage, [www.xspraypharma.com](http://www.xspraypharma.com).

For information on how your personal data is processed, see the integrity policy that is available at Euroclear Sweden AB's webpage <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>.

## Annual general meeting in Xspray Pharma AB (publ) on 12 May 2026

The options below comprise the proposals submitted by the board of directors and the nomination committee which are included in the notice convening the annual general meeting.

<b>2. Election of a chairman of the meeting</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>4. Approval of the agenda</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>6. Determination of whether the meeting was duly convened</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8.a Resolution regarding adoption of the income statement and balance sheet and, where applicable, the consolidated income statement and consolidated balance sheet</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8.b Resolution regarding allocation of the company's profit or loss according to the adopted balance sheet</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8.c Resolution regarding discharge from liability for board members and the managing director</b>
<b>8.c.1 Anders Ekblom</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8.c.2 Anders Bladh</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8.c.3 Markus Haeberlein</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8.c.4 Christine Lind</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8.c.5 Robert Molander</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8.c.6 Anne Prener</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8.c.7 Carl-Johan Spak</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8.c.8 Maris Hartmanis (former board member)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8.c.9 Torbjörn Koivisto (former board member)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>

<b>8.c.10 Per Andersson (CEO)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9. Determination of the number of board members and auditors</b>
<b>9.1 Number of board members</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9.2 Number of auditors</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>10. Determination of fees for the board of directors and auditors</b>
<b>10.1 Fees to the board of directors</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>10.2 Fees to the auditors</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>11. Election of members of the board of directors</b>
<b>11.a Anders Ekblom (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>11.b Anders Bladh (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>11.c Markus Haerberlein (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>11.d Christine Lind (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>11.e Robert Molander (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>11.f Anne Prener (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>11.g Carl-Johan Spak (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>12. Election of the chairman of the board of directors Anders Ekblom (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>13. Election of auditors and, where applicable, deputy auditors</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>14. Resolution on principles for the appointment of the nomination committee</b> Yes <input type="checkbox"/> No <input type="checkbox"/>

<p><b>15. Presentation of the board of directors' remuneration report for approval</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>16. Resolution on the board of directors' proposal regarding a long-term incentive program 2026 (LTIP 2026) based on warrants and employee stock options</b></p>
<p><b>16.a Resolution on adoption of Warrant Programme 2026</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>16.b Resolution on issue and transfer of warrants to participants at a price corresponding to the market value</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>16.c Resolution on issue and transfer of warrants to secure delivery of shares pursuant to the terms of the employee stock options</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>17. Resolution on the board of directors' proposal to adopt a long-term incentive program based on performance-based share rights for employees at Xspray (PSU 2026)</b></p>
<p><b>17.a Resolution on adoption of PSU 2026</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>17.b Resolution on (i) introduction of a new class of shares by amending the articles of association, (ii) authorisation for the board of directors to resolve to issue new class C shares, (iii) authorisation for the board of directors to resolve on repurchase of class C shares, and (iv) transfer of own ordinary shares to participants and in the market</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>17.c Resolution on equity swap agreement with a third party</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>18. Resolution to authorize the board of directors to issue new shares, warrants and/or convertibles with or without deviation from the shareholders' preferential rights</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>